GEODON Pdr+Solv for Soln for Inj 20 Base Milligrams
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
28-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE
Available from:
Pfizer Limited
Dosage:
20 Base Milligrams
Pharmaceutical form:
Pdr+Solv for Soln for Inj
Authorization date:
2002-03-08
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
GEODON 20 mg/ml powder and solvent for solution for injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial contains ziprasidone mesilate to deliver 20 mg of ziprasidone. After reconstitution, 1ml of solution for
injection contains 20 mg ziprasidone.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder and Solvent for solution for injection.
White to off-white powder
Clear colourless solvent
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Ziprasidone powder and solvent for solution for injection is indicated for the rapid control of agitation in patients with
schizophrenia, when oral therapy is not appropriate, for a maximum of 3 consecutive days.
Treatment with ziprasidone powder and solvent for solution for injection should be discontinued, and the use of oral
ziprasidone should be initiated, as soon as clinically appropriate.
4.2 Posology and method of administration
For intramuscular use only.
Intravenous administration must be avoided.
Treatment with the intramuscular formulation should only be used in patients, where treatment with an oral formulation
is considered to be inappropriate.
Adults
The recommended dose is 10 m
Read the complete document
